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Abstract 25 
Microfluidics has recently emerged as a new method of manufacturing liposomes, which allows for 26 
reproducible mixing in miliseconds on the nanoliter scale. Here we investigate microfluidics-based 27 
manufacturing of liposomes. The aim of these studies was to assess the parameters in a microfluidic 28 
process by varying the total flow rate (TFR) and the flow rate ratio (FRR) of the solvent and aqueous phases. 29 
Design of Experiment and multivariate data analysis were used for increased process understanding and 30 
development of predictive and correlative models. High FRR lead to the bottom-up synthesis of liposomes, 31 
with a strong correlation with vesicle size, demonstrating the ability to in-process control liposomes size; 32 
the resulting liposome size correlated with the FRR in the microfluidics process, with liposomes of 50 nm 33 
being reproducibly manufactured. Furthermore, we demonstrate the potential of a high throughput 34 
manufacturing of liposomes using microfluidics with a four-fold increase in the volumetric flow rate, 35 
maintaining liposome characteristics. The efficacy of these liposomes was demonstrated in transfection 36 
studies and was modelled using predictive modelling. Mathematical modelling identified FRR as the key 37 
variable in the microfluidic process, with the highest impact on liposome size, polydispersity and transfection 38 
efficiency. This study demonstrates microfluidics as a robust and high-throughput method for the scalable 39 
and highly reproducible manufacture of size-controlled liposomes. Furthermore, the application of 40 
statistically based process control increases understanding and allows for the generation of a design-space 41 
for controlled particle characteristics.  42 
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1.Introduction   43 
Liposomes are well established as delivery systems and immunological adjuvants and there are a wide 44 
range of methods employed in their production. For example, multilamellar vesicles (MLV) can be formed 45 
by the dispersion of a dried lipid film and small unilamellar vesicles (SUV) can then be produced by 46 
sonication (Lapinski et al., 2007; Maulucci et al., 2005), extrusion (de Paula Rigoletto et al., 2012; Olson et 47 
al., 1979), or high-pressure homogenization (Barnadas-Rodriguez and Sabes, 2001; Pupo et al., 2005). 48 
However, sonication may lead to sample contamination by metallic residues from the probe tip, lipid 49 
degradation and lack of scalability (Wagner and Vorauer-Uhl, 2011). Homogenization techniques, shear or 50 
pressure induced size reduction, circumvent protein or lipid degradation and are frequently used to reduce 51 
the size and lamellarity of MLV (Wagner and Vorauer-Uhl, 2011). Maintenance of constant temperatures 52 
throughout these processes can be difficult, with restrictions to relatively small working volumes and 53 
quantities; however, continuous and heat controlled homogenization techniques have been developed to 54 
help overcome some of these problems (Riaz, 1996; Wagner and Vorauer-Uhl, 2011). 55 
 56 
As an alternative to these methods, microfluidics is a relatively new area of liposome synthesis, where the 57 
small dimensions in a micromixer allow for fast mixing, dominated by diffusion or convection (Whitesides, 58 
2006).  Microfluidics refers to fluid handling methods in a controlled volume, typically below millimeter 59 
scales, which allows for implementation of the mixing process into planar chips (Squires and Quake, 2005). 60 
The application of microfluidics for liposome synthesis in novel lab-on-a-chip based devices dramatically 61 
reduces time for sample preparation as well as costs associated with experimental work and may 62 
additionally be fully software controlled to aid process robustness and reproducibility (van Swaay, 2013). 63 
Various micromixers have been designed and applied for the manufacturing of liposomes based on different 64 
channel layouts (Pradhan et al., 2008) including flow focusing (Davies et al., 2012; Jahn et al., 2004), 65 
droplet based (Teh et al., 2008), and T- or Y- shaped mixers (Kurakazu and Takeuchi, 2010). In this study, 66 
a staggered herringbone micromixer (SHM) (Stroock et al., 2002) which induces chaotic advection, is used. 67 
The chaotic advection mixing profile allows for stretching and folding of fluid streams over the channels 68 
cross-sectional area, increasing mass transfer together with the herringbone type structures on the channel 69 
floor (Stroock et al., 2002). Here, a SHM was used together with the automated mixing platform 70 
NanoAssemblr (Precision NanoSystems, Inc.). This system enables rapid, reproducible and scalable 71 
manufacture of homogeneous next-generation nanoparticles and liposomes (Belliveau et al., 2012; 72 
Zhigaltsev et al., 2012). Lipid dissolved in solvent is pumped into one inlet and aqueous buffer into the other 73 
inlet of the microfluidic mixing cartridge (Figure 1). It has been suggested that a nanoprecipitation reaction 74 
results in the formation of nanoparticles (Karnik et al., 2008; Zhigaltsev et al., 2012). This reaction takes 75 
place at the interface of the solvent and aqueous streams. Liposome formation is based on polarity 76 
alterations throughout the chamber and an increase in the surface area of the fluid interface occurs, as the 77 
fluids are folded over on top of each other aided by the channel design and grooves on the channel floor 78 
(Figure 1, small). The rate of polarity increase and the subsequent following the formation of liposomes is 79 
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user-controlled by alterations in flow rates of the separate streams as well the ratios of aqueous to solvent 80 
stream  as demonstrated for liposomes (Bally et al., 2012; Zhigaltsev et al., 2012) and polymeric 81 
nanoparticles (Bally et al., 2012). Furthermore, the option of parallelization of the mixing cartridges allows 82 
for scalability as a high throughput method (Belliveau et al., 2012). 83 
 84 
The development and optimization of new processes and methods can be a time consuming task, 85 
especially when applying the traditional one-factor-at-a-time (OFAT) method, where only one factor is 86 
optimized while all other factors remain constant. Adopting this approach may also result in the optimum 87 
process or formulation being overlooked as well as possible factor-interactions (Montgomery et al., 1997). 88 
An alternative approach is to adopt Design of Experiments (DoE), a statistical optimization method, 89 
favorably used in pharmaceutical and biopharmaceutical process development and optimization 90 
(Lawrence, 2008; Singh et al., 2011; Vandervoort and Ludwig, 2002). DoE is a systematic approach of 91 
creating structured experiments, measuring or detecting the effect of changes to a pre-defined response. 92 
Product quality, as well as process understanding is maximized with a minimal number of experiments 93 
performed. In DoE, the factors are defined as the variables in a process and selected responses define the 94 
properties of the system that is investigated. Factors are the tools used for manipulation of the system, 95 
which following influence the responses. The aim is to connect the variation in the factors to the resulting 96 
responses, and link the information using a mathematical model. DoE does not only investigate statistical 97 
VLJQLILFDQWIDFWRUVLQYROYHGLQDSURFHVVPDLQHIIHFWVLWDOVRLGHQWL¿HVLQWHUDFWLRQVEHWZHHQIDFWRUVDQG98 
UHVSHFWLYH LQÀXHQFHRQ the desired output variable (Eriksson, 2008; Mandenius and Brundin, 2008).  A 99 
second statistical tool, multivariate data analysis (MVDA), allows for the analysis of more than one statistical 100 
variable at a time by reducing dimensionality in a data set by its transformation (Wold et al., 2001a; Wold 101 
et al., 2001b). MVDA is used for identifying patterns and relationships between several variables 102 
simultaneously (Eriksson, 2006). It predicts the effect of changing one variable to other variables and is 103 
applied for data analysis, data mining, classification (e.g. cluster analysis or outlier detection), regression 104 
analysis and predictive modeling, frequently used in pharmaceutical and biopharmaceutical processes 105 
(Eriksson, 2006; Pasqualoto et al., 2007; Rathore et al., 2011). Both tools, DoE and MVDA, are statistical-106 
based, process understanding and optimization tools that build and describe knowledge around a specific 107 
application, which ultimately supports the development of confidence and enhanced understanding, as well 108 
as robustness of a process. 109 
This present study first investigated microfluidics as a new method for manufacturing of cationic liposomes 110 
using the 1DQR$VVHPEOU To achieve this 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 111 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were used to formulate liposomes. This combination 112 
of the fusogenic lipid DOPE with the cationic lipid DOTAP, is a frequently used composition due to its high 113 
in vitro transfection efficiency and optimal immune response (McNeil et al., 2010; Liu and Huang, 2002) 114 
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and was therefore chosen to allow correlation of the systems produced via this new production method with 115 
previous studies. 116 
 117 
2. Materials and Methods  118 
2.1 Materials  119 
1,2-dioleoyl-sn-glycero-3-phsphoethanolamine (DOPE) and 1,2-dioleoyl-3-trimethylammonium-propane 120 
(DOTAP) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL) (purity >99%). Ethanol and 121 
chloroform (all HPLC grade) were purchased from Fisher Scientific (Leicestershire, UK). LipofectinTM 122 
reagent was obtained from Invitrogen Life Technologies and the luciferase assay kit and CellTiter 96® 123 
AQueous One Solution Cell Proliferation Assay were both obtained from Promega (Madison, WI). Serum 124 
free and antibiotic free medium (opti-0(0 'XOEHFFR¶V PRGLILHG (DJOHV PHGLXP '0(0 /-125 
glutamine/Penicillin-Streptomycin and foetal bovine serum (FBS) were purchased from Gibco-Invitrogen 126 
Ltd (Paisley, UK) (all cell culture grade). gWizTM Luciferase was obtained from Genovac GmbH, Germany. 127 
COS-7 cells (GMP grade) were purchased from European collection of cell cultures (ECACC), a Health 128 
Protection Agency Culture Collection (Salisbury, UK). 129 
 130 
2.2  Micromixer  131 
The micromixer was obtained from Precision NanoSystems Inc., with molded channels of 200 µm in width 132 
and 79 µm in height with herringbone features of 50 x 31 µm in poly(dimethylsiloxane). Connections of 133 
disposable 1mL syringes to the two inlet streams to the chip was done by fluid connectors.  Liposome 134 
formulations using the micromixer were perforŵĞĚ ŽŶ Ă ďĞŶĐŚƚŽƉ EĂŶŽƐƐĞŵďůƌ ? instrument 135 
 ?EĂŶŽƐƐĞŵďůƌ ? ? WƌĞĐŝƐŝŽŶ EĂŶŽ^ǇƐƚĞŵƐ /ŶĐ ? ?. The two inlet streams comprised lipids dissolved in 136 
ethanol and aqueous buffer (Tris, 10mM, pH 7.4), syringe pumps allowed for controlling the flow rates 137 
and the flow ratios between the two inlet streams. 138 
 139 
2.3 Liposome Preparation 140 
'23(DQG'27$3ȝ0ROHVZHUHGLVVROYHGLQHWKDQROHere, an equal molar lipid ratio was used, a 141 
standard ratio in cationic liposome-DNA transfection studies as reported previously (Felgner et al., 1994; 142 
Moghaddam et al., 2011). The ethanol-lipid solution was injected into the first inlet and an aqueous buffer 143 
(Tris 10 mM; pH 7.4) into the second inlet of the microfluidic mixer (Figure 1). During initial studies, the TFR 144 
of aqueous buffer and lipid phase were varied from 0.5 mL/min to 2 mL/min and the FRR of the solvent and 145 
aqueous phases was varied from 1:1 to 1:5. Values of TFR and FRR were extrapolated from previous 146 
reported nanoprecipitation methods using a SHM design with a channel diameter of 200 ȝm (Zhigaltsev et 147 
al., 2012) as well as based on preliminary screening prior to this work. The resulting aqueous dispersions 148 
of liposome formulations, as formed by the mixing of the two adjacent streams, were collected from the 149 
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outlet stream and subsequently dialysed over night against Tris buffer (10 mM; pH 7.4) to remove any 150 
residual solvent.  151 
 152 
2.4 Liposome Characterisation 153 
The dynamic light scattering (DLS) technique was used to report the intensity mean diameter (z-average) 154 
and the polydispersity of all liposome formulations (Malvern Zetasizer Nano-ZS (Malvern Instruments, 155 
:RUFV8.7KHPHDVXUHPHQWVRIYHVLFOHVL]HDQGSRO\GLVSHUVLW\ZHUHFDUULHGRXWDWÛ&LQ7ULVEXIIHU156 
(1/10 dilution; 1 mM, pH 7.4). Liposome zeta potential was measured in Tris buffer (1 mM, pH 7.4) using 157 
the Malvern Zetasizer Nano-ZS (Malvern Instruments, Worcs., UK). All measurements were undertaken in 158 
triplicates. 159 
 160 
2.5 HPLC  161 
Lipid quantification of the liposome formulations was carried out using an Agilient 1200 series HPLC 162 
connected to an SEDEX 90 evaporative light scattering detector (ELSD). A Phenomenex® Luna ȝ&163 
(2) 100A 150 x 4.6 mm column was used. An isocratic flow method was employed with 85% methanol and 164 
15% 0.1% TFA water at a flow rate of 1 mL/min. The ELSD temperature was set at 52oC. The total run time 165 
was 20 minutes. 166 
 167 
2.6 DNA lipoplex preparation for in vitro transfection 168 
To perform in vitro studies, OLSRSOH[HVZDVSUHSDUHGE\GLOXWLQJȝORI689VROXWLRQȝPROHVWR169 
ml with Opti-MEM, and then incubated for 40 minutes at room temperature. After incubation, 0.35 ml of 170 
Opti-0(0FRQWDLQLQJȝJSODVPLG'1$ZDVDGGHGPL[HGZLWKOLSRVRPHVROXtion and incubated again 171 
for a further 15 min at room temperature. The resultant lipoplex mixture was then diluted to a final volume 172 
of 3.5 ml with Opti-MEM. The lipid/DNA charge ratio for in vitro study was +1.7/1.  173 
 174 
2.7 In Vitro Transfection of COS-7 Cells  175 
African green monkey kidney cells (COS-7 cells) were cultured at 37 °C under 5% CO2 LQ 'HOEHFFR¶V176 
modified Eagles medium (DMEM). Medium was supplemented with 4 mM L-glutamine, 10% (v/v) foetal 177 
ERYLQHVHUXP)%6SHQLFLOOLQȝJPODQGVWUHSWRP\FLQȝJPOKRXUVSULRUWRWUDQVIHFWLRQWKH178 
COS-7 cells were plated at a cell concentration of 1 × 105 cells/mL in 1 mL of medium in a 12-well plate 179 
and were incubated overnight. Cells were washed with 1 mL of opti-MEM before lipoplexes were added to 180 
the cells. 1 mL of the SUV-'1$VROXWLRQȝPROHWRWDOOLSLGFRQWHQWFRQWDLQLQJȝJSODVPLG'1$181 
was added to each well. Each transfection was performed in triplicate. After 5 hours of incubation time at 182 
37 °C in 5% CO2, the medium was replaced with growth medium (DMEM) containing 10% FBS and the 183 
cells were incubated for further 48 hours. The transfection efficiency of each formulation was measured by 184 
determination of the percentage of luciferase activity in each sample to the control. In this study this value 185 
is reported as luciferase activity (%) and Lipofectin was the control transfection reagent.  186 
7 
 
 187 
2.8 Cytotoxicity Study  188 
Lipoplex formulations used in the cytotoxicity study were same as described above. COS-7 cells were 189 
transferred on a 96-ZHOOSODWHDQGLQFXEDWHGIRUKRXUVDW&LQ'0(0PHGLXPȝ/RI076UHDJHQW190 
(CellTiter 96® AQueous One Solution Cell Proliferation Assay) was added to each well. The MTS reagent 191 
is bioreduced by the cells into a red formazan product, which indicates the presence of metabolically active 192 
cells. After 4 hours incubation at 37 °C, in a 5% humid CO2 atmosphere, the quantity of produced formazan 193 
was measured on microplate reader (Thermo Scientific Molecular Spectrum plate reader) at A490, with the 194 
absorbance reading being directly proportional to the number of living cells in the medium. In this study, 195 
cell viability was calculated and expressed as a percentage to the positive control (i.e., cells and medium). 196 
 197 
2.9 Statistical analysis 198 
All experiments were performed in triplicates with calculation of means and standard deviations. Statistical 199 
significance was determined by a one-way analysis of variance (ANOVA) on all data, and determined to 200 
0.05 confidence intervals (p<0.05).  201 
 202 
2.10 Design of experiments 203 
The significance of the factors TFR (0.5 to 2 mL/min) and FRR (1:1 to 1:5) on liposome size, polydispersity 204 
and transfection efficiency were investigated in a Design of experiments (DoE) study (MODDE version 10.0, 205 
Umetrics). We used multiple linear regressions (MLR), which fits one response at a time, based on the 206 
assumption that the responses are independent. A quadratic response surface model (RSM) was 207 
performed. The collected data was used to estimate the coefficients of the model and assess for statistical 208 
significance. The sum of squares of the residuals was minimized in the model. The aim was to obtain small 209 
variation for the coefficients and minimize the prediction errors, which was achieved with least square 210 
regression analysis. Prediction plots (response surfaces) were used for model interpretation and 211 
assessment of optimal regions in the model prediction. Models were validated by analysis of variance 212 
(ANOVA), which identified the goodness of fit and prediction (R2 and Q2) and the significance of each factor 213 
in the model. Regression model significance test identified the validity of a model by dividing the mean 214 
squares of the regression by the mean square of the residual, which allowed for determination of the 215 
probability value p. With p< 0.05, the model determined was good. Lack of fit (LOF) test was performed to 216 
investigate the model error and the replicate error.  A model showed no lack of fit when a sufficiently small 217 
model error and a good data fit were obtained, indicated by a p-value larger than the critical reference 0.05.  218 
 219 
2.11 Multivariate Data Analysis 220 
Principal Component Analysis (PCA) and Partial Least Square (PLS) regression analysis was performed 221 
(SIMCA version 13.0, Umetrics) in order to analyse more than one variable at a time. The relationship 222 
between the variables TFR and FRR and the responses (liposome size, polydispersity and transfection 223 
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efficacy) was displayed in a loading plot, using all experimentally obtained raw data in this study. Weights 224 
were selected to maximize the correlation. For interpretation, a line from a selected variable was drawn 225 
though the origin and X- and Y-variables were projected on the line. Variables opposite to each other were 226 
determined as negatively correlated, positive correlation was determined with variables adjacent to each 227 
other.  228 
 229 
3. Results and Discussion 230 
3.1 Liposome manufacturing by microfluidics ± vesicle size can be in-process controlled. 231 
Liposomes consisting of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-232 
3-phosphoethanolamine (DOPE) were formulated using the microfluidics method with a SHM design. In 233 
this study, the aim was to optimise parameters to control particle size by varying the TFR from 0.5 mL/min 234 
to 2 mL/min and varying the FRR of the solvent/aqueous phases from 1:1 to 1:5. It can be seen from Figure 235 
2A that as the aqueous/ethanol FRR was increased, a reduction in liposome size was detected. However, 236 
increasing the TFR from 0.5 mL/min to 2 mL/min did not significantly affect the vesicle size for the FRR of 237 
1:1, 1:3 and 1:5 (Fig 2A). Liposomes formed at 1:5 solvent/ aqueous formulation were smaller in size and 238 
around 50 - 75 nm compared to the 1:1 solvent/aqueous formulation (175 ± 200 nm; Figure 2A). The FRR 239 
strongly affects the polarity increase throughout the chamber as well as the final solvent concentration. At 240 
higher FRR (1:5), the final solvent concentration is reduced, thus reducing the production of larger 241 
liposomes due to particle fusion and lipid exchange (Ostwald ripening) after complete mixing is achieved. 242 
Previous work using hydrodynamic flow-focusing techniques have also reported the decrease in liposome 243 
size with the increase in FRR (Jahn et al., 2010; Zook and Vreeland, 2010), in agreement with results in 244 
this study. The zeta potential of the liposomes formed using this method was maintained despite alterations 245 
in flow rates and ratios with the liposomes had a positive zeta potential of around 45 - 60 mV (Figure 2B). 246 
This is in agreement with data previously reported for DOPE:DOTAP prepared by the lipid-hydration method 247 
following sonication (McNeil et al., 2010). Furthermore, homogenous suspensions were quickly achieved 248 
using the microfluidics method as the polydispersity was around 0.2 to 0.5 (Figure 2C); the increase in FRR 249 
had the highest impact on resulting PDI. 250 
Overall, vesicle size was shown to be in-process controlled through the aqueous/ethanol flow rate ratio. 251 
The TFR was shown to have no significant effect on the liposome size, zeta potential and polydispersity 252 
indicating the potential of the microfluidics system to work at higher volumetric flow rates and higher 253 
production outputs, which represents a key advantage of the microfluidics-based manufacturing of 254 
liposomes. 255 
 256 
3.2 Lipid content quantification by ELSD 257 
To investigate the lipid recovery of formulations manufactured at different TFR and FRR in the 258 
1DQR$VVHPEOU ZH TXDQWLILHG WKH OLSLGV LQ WKH OLSRVRPH IRUPXODWLRQV /LSLG FRPSRVLWLRQ LV XVXDOO\259 
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quantified via high performance liquid chromatography after extraction of the lipids in an organic phase. 260 
Here, we used an evaporative light scattering detector (ELSD); a mass analyzer that allows for 261 
quantification of lipids based on light scattering. We quantified the lipid content (DOPE and DOTAP) in each 262 
formulation separately and related to it the initial lipid amount present in the solvent stock. The liposome 263 
IRUPXODWLRQVZHUHSUHSDUHGLQWKH1DQR$VVHPEOUDWIORZUDWHVIURPP/PLQWRP/PLQDQG)55RI264 
1:1, 1:3 and 1:5 (solvent: aqueous ratio). Lipid recovery was above 87% for all formulations, with no 265 
significant differences (p>0.05) within all experiments (Figure 3). This suggests that lipid content remains 266 
independent of flow rates and fORZ UDWLRV LQ WKH 1DQR$VVHPEOU and confirms the suitability of the 267 
microfluidics method for producing small liposomes with high lipid recovery.  268 
 269 
 270 
3.3 Biological activity of liposomal systems - In Vitro Transfection efficiency  271 
To consider the efficacy of the liposome systems prepared using microfluidics, their ability as transfection 272 
agents was tested using a standard in vitro assay. The commercially available  LipofectinTM was used as a 273 
control since it has been extensively used to transfect a wide variety of cells (Fortunati et al., 1996; Malone 274 
et al., 1989) DQGDSODVPLGFRQWDLQLQJWKHOXFLIHUDVHJHQHJ:L]/XFLIHUDVHZDVXVHG7KHtransfection 275 
efficiency of each formulation was determined by measuring the percentage of luciferase activity in each 276 
sample to the control (/LSRIHFWLQ) reported as luciferase activity (%) (Figure 4A). Whilst in general the 277 
liposomes prepared at a solvent/aqueous flow rate of 1:3 gave the highest transfection rate, changes in the 278 
total flow rate did not significantly influence the liposomes transfection activity again demonstrating this 279 
method of liposome production is applicable for high-throughput production of liposomes (Figure 4A). The 280 
size, charge and lipid/NDA ration have previously been shown to effect transfection efficiency (Aljaberi et 281 
al., 2007; Caracciolo et al., 2007). Given that the lipids/DNA ratio, as well as the cationic zeta potential has 282 
been constant in each lipoplex formulation, the resulting difference in transfection efficacy may be due to 283 
differences in liposome sizes (Figure 2A) as previously investigated (McNeil et al., 2010; Esposito et al., 284 
2006; Felgner et al., 1987; Kawaura et al., 1998).  285 
 286 
The potential toxicity of these formulations was tested to verify that transfection efficacy was independent 287 
of cell viability and toxicity. Overall, cell viabilities remained above 60% for all experiments performed with 288 
no significant (p>0.05) difference between the formulations (Figure 4B). Neither the flow rates nor the flow 289 
ratios were shown to affect the cell viability. Any gene delivery vector should ideally be of low toxicity, and 290 
should additionally be easy to manufacture in a robust and reproducible process (Lui and Huang, 2003). 291 
Here, the microfluidics process was shown to fulfil those requirements.  292 
 293 
3.4 Statistical significance of the factors flow rate ratio and total flow rate ± Design of Experiment 294 
studies 295 
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Given that the liposomes prepared by microfluidics were shown to be effective gene delivery vehicles and 296 
that the process parameters adopted were shown to impact on their efficacy, the statistical significant effect 297 
of the factors TFR and FRR on liposome size, polydispersity and transfection efficiency (luciferase activity) 298 
were further investigated in a response surface modeling in a DoE study.  Here, a quadratic interaction 299 
model investigated the factors TFR and flow rate ratio FRR as well as the interaction terms TFR*TFR, 300 
FRR*FRR and TFR*FRR.  301 
 302 
The significant model terms determined in the model are shown in Table 1. The significant factors in the 303 
size model (FRR, TFR, FRR*FRR) suggested that both factors together control the liposome size 304 
PDQXIDFWXUHG ZLWK WKH 1DQR$VVHPEOU 7KH VLJQLILFDQW LQWHUDFWLRQ WHUP RI )55)55 VXJJHVWV WKH305 
importance of the solvent/aqueous ratios to the overall liposome size, emphasizing the FRR to be of high 306 
importance when controlling the liposome size in a microfluidics method. The response surface plots 307 
(Figure 5) show the combinatorial effect of alterations in FRR and TFR in tKH1DQR$VVHPEOUSURFHVVWR308 
the liposome size, polydispersity and transfection efficacy. The model predicted minimal vesicle sizes of 60 309 
nm for high flow rates (2 mL/min) and at high flow rate ratios (1:5). This underlies the theory of liposome 310 
formation b\PLFURIOXLGLFPL[LQJLQWKH1DQR$VVHPEOU7KHLQFUHDVHLQDTXHRXVSKDVHIORZDQGYROXPH311 
increases the amount of polar phase available and thus enhances the rate of polarity increase, shown by 312 
the significant interaction term FRR*FRR (Table 1). This affects the nanoprecipitation reaction, as smaller 313 
vesicles should be generated with a higher amount of polar phase available, emphasizing the theory of 314 
nanoprecipitation reaction and liposome formation in the microfluidic mixing method.  In the ANOVA 315 
analysis (Table 2) we could identify the statistical significance of the models generated, where all three 316 
models (size, polydispersity and transfection efficacy) generated were determined as statistical significant.  317 
The predictions for the PDI model identified the coefficient FRR as the only significant model term (Table 318 
2). The mathematical model confirmed statistical significance for the factor FRR as the only impact to the 319 
liposome PDI. Low PDIs were predicted for low FRRs (1:1) (Figure 5 B), the increase in FRR, which lead 320 
to an increase in PDI was already observed above (Figure 2C) and confirmed that the PDI will inevitably 321 
increase once the FRR will be increase in the process. The model for the transfection efficiency further 322 
confirmed the significance of the factor FRR to resulting luciferase activity. Luciferase activities above 180% 323 
were predicted for FRR between 1:2 and 1:4, independent of the TFR used (Figure 5C). These predictions 324 
allow for targeted selection of flow properties in the micromixer depended on desired vesicle characteristics 325 
and transfection efficiencies anticipated.  These findings further underline the suggestions that the 326 
alterations of the TFR mainly lead to an increase in productivity by enhancing the throughput in the method. 327 
 328 
3.5 Correlation of factors in the microfluidics process to biological responses and particle 329 
characteristics - Multivariate data analysis  330 
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Multivariate analysis tools are frequently used to find relationships amongst variables (X) and response (Y). 331 
Partial least square (PLS) analysis deals with X and Y variables, and is used for regression modeling of X 332 
and Y. It can be used to predict Y from X and reveals how the variables and responses are related to each 333 
other. Principal components (PC) are fitted through the multidimensional data set in order to generate 334 
coordinates of each data point, which are used to plot the data set onto a plane in a loading plot, which can 335 
be subsequently used for data interpretation. 336 
 337 
In this study, two PCs were added in the PLS analysis, which were depicted in the loading scatter plot in 338 
order to evaluate the effect of factors (TFR and FRR) to the responses (liposome size, PDI and transfection 339 
efficacy). The coefficient plot (Figure 6A) reveals the significance of the factors as well as the responses 340 
for the two principal components fitted to the data set. Here, the factor TFR was the only factor significant 341 
in the second PC. The factor FRR, as well as the responses transfection efficacy and size were shown to 342 
be highly statistical significant in the first principal component (Figure 6A). The response PDI was significant 343 
in both principal components. The loading scatter plot (Figure 6B) indicated that the TFR was in the upper 344 
left quadrant, opposite to the response liposome size. The coefficient plot (Figure 6A) identified that the 345 
factor TFR and the response size were significant in different PCs, which indicates no correlation. 346 
Furthermore, the response PDI was the only further response significant in the second PC, which suggests 347 
that the factor TFR is independent of liposome size and transfection efficiency. Furthermore, the FRR factor 348 
was shown to directly correlate to the liposome polydispersity (Figure 6B), both highly significant in the first 349 
PC, which has been previously seen in the DoE model (Table 1). Thus, the analysis predicts an increase 350 
in polydispersity in a liposome formulation once the FRR is increased. The correlation between the 351 
responses size and transfection efficiency indicated, as both responses are situated closely adjacent to 352 
each other in the loading plot, both significant in the first PC, a direct correlation (Figure 6B). This indicates 353 
that the increase in liposome size results in a higher transfection efficiency, which has been seen in the 354 
above DoE model and gives a mathematical proof of previous findings; larger particles correlate with greater 355 
level of transfection efficiency than smaller complexes at constant lipid/DNA ratio (E McNeil et al., 2010; 356 
Esposito et al., 2006; Felgner et al., 1987; Kawaura et al., 1998).  357 
 358 
The factor FRR was shown to have the highest impact to the responses, indicated by a very small 95% 359 
confidence interval in the coefficient plot (Figure 6A). As seen in the DoE study, the FRR was shown to be 360 
highly significant in the size, PDI and transfection efficiency model. Therefore, we can conclude that FRR 361 
needs crucial optimization in a formulation in order to develop a method with not only desired particle 362 
characteristics (size and PDI) but also in the case of this formulation the anticipated transfection efficiencies 363 
for in-vitro gene delivery and application of lipoplexes. Overall, the results indicate that the FRR in the 364 
microfluidic process has a strong relevance to the formation of size-controlled vesicles with MVDA studies 365 
confirm the significance of FRR in the microfluidics process for the formation of liposomes. 366 
 367 
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The systematic application of statistical based process control and optimization requires not only fewer 368 
experiments to find a local optima, it also it reveals factor interactions and can be used for process 369 
simulations. Overall, it will lead to better understanding of a process, which assists in development and 370 
scale-up. It is a cost-effective method providing deep understanding in a process (Singh et al., 2005). 371 
Gabrielsson et al. reviewed multivariate methods in pharmaceutical applications, which range from factorial 372 
designs to multivariate data analysis and regression analysis, where studies reported improved process 373 
and product quality (Gabrielsson et al., 2002).  Where DoE is frequently used to find local optima, PCA and 374 
PLS are mainly applied to gain deeper understanding and information about a process and the effect of 375 
how factors influence the responses. In this study, we have developed a statistical valid regression model, 376 
which allows for prediction of liposome sizes, polydispersity and transfection efficiencies as a function of 377 
variables in the microfluidics-based manufacturing method. Furthermore, the application of MVDA allowed 378 
for deeper understanding of process settings that will lead to increased process control with a defined 379 
product quality outcome. The combination of multivariate methods and experimental design in any 380 
pharmaceutical or biopharmaceutical process development strategies is a powerful tool towards developing 381 
new processes and finding optima within a defined region of factors by speeding up a developing process.  382 
 383 
4. Conclusion 384 
In this paper, we have used a microfluidics-based liposome manufacturing method and varied the process 385 
parameters total flow rate and flow rate ratio to produce liposomes of defined size.  Using microfluidics, 386 
homogenous liposomes suspensions can be prepared in a high throughput method setup. Liposomes 387 
manufactured by this method were shown to give reproducible transfection results in standard transfection 388 
protocols. The application of statistical-based methods (Design of Experiments and Multivariate Data 389 
Analysis) revealed the mathematical relationship and significance of the factors total flow rate and flow rate 390 
ratio in the microfluidics process to the liposome size, polydispersity and transfection efficacy. We show 391 
that the here applied methods and mathematical modeling tools can efficiently be used to model and predict 392 
liposome size, polydispersity and transfection efficacy as a function of the variables in the microfluidics 393 
method. Furthermore, the advantages of microfluidics as a bottom-up liposome manufacturing method have 394 
been shown, anticipating microfluidics and associated lab-on-a-chip applications will become the choice of 395 
liposome manufacturing in future. With these studies, we have demonstrated the advantages of 396 
incorporating additionally statistical based methods into a development process. Application of statistical 397 
based process control and optimization tools like DoE and MVDA will enhance the reproducibility in a 398 
process and aid for generation of a design space. This will increase the understanding and confidence in a 399 
process setting and allow for predictive and correlative comparisons between the critical process 400 
parameters and their effect on desired critical quality attributes, leading to a desired and robust product 401 
quality 402 
 403 
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Tables 523 
 524 
Table 1: Coefficient list for the responses size, zp and PDI. Coefficients were determined as statistically 525 
significant (p< 0.05). 526 
 527 
Response Significant coefficients 
Size (nm) TFR, FRR, FRR*FRR 
PDI FRR, FRR*FRR 
Transfection Efficiency FRR, FRR*FRR 
 528 
 529 
 530 
 531 
 532 
Table 2: ANOVA for the responses size, z and PDI. The p-statistics were analysed as well as the Lack-of-533 
fit (LOF), together with fit  power (R2) and predictive power (Q2). 534 
 535 
ANOVA Size PDI Transfection 
Efficiency 
Regression p 0.000 0.001 0.001 
LOF p 0.255 0.973 0.585 
R2 0.989 0.885 0.889 
Q2 0.963 0.789 0.522 
Model Significant? Yes Yes Yes 
  536 
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Figure legends 537 
 538 
Figure 1: Schematic of liposome formulation process. Lipids dissolved in ethanol and an aqueous buffer 539 
are injected into separate chamber inlets. Mixing takes place in the chamber (small picture), designed with 540 
grooves on the channel floor to aid chaotic advection between both streams.  Depicted are the critical 541 
process parameters and the critical quality attributes.  542 
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 543 
Figure 2.  Liposome characteristics. (A) Vesicle size (z-average), (B) zeta potential and (C) polydispersity 544 
of DOPE:DOTAP formulations manufactured by microfluidic mixing. Results are the mean of triplicate 545 
formulations ± SD.  546 
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 547 
Figure 3. Quantification and recovery (%) of lipids (DOPE+DOTAP) by HPLC. Results are the mean of 548 
triplicate formulations ± SD. 549 
 550 
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 551 
Figure 4. (A) Comparison of transfection efficiency of cationic nanoparticles. Liposomes were complexed 552 
with gWiz plasmid DNA expressing firefly luciferase. (B) Relative cell viability of nanoparticles formulated 553 
with distilled water. Results denote mean ± SD, n = 3. 554 
 555 
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556 
Figure 5. The response surface plots in the DoE study for the responses size (A), PDI (B) and transfection 557 
efficacy (C) as a function of flow rate ratio and total flow rate. All three models were determined as statistical 558 
significant in an ANOVA analysis. 559 
 560 
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561 
Figure 6. Results from the PLS regression analysis colored according to model term. (A) Coefficient plot 562 
including 95% confidence interval for the two principal components. (B) The loading scatter plot indicating 563 
significance of the factors (X) and responses (Y) to each other.  564 
 565 
